Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone44-0-15-3475-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$248.07 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
Novocure (NASDAQ:NVCR) Frequently Asked Questions
What is Novocure's stock symbol?
Novocure trades on the NASDAQ under the ticker symbol "NVCR."
How were Novocure's earnings last quarter?
Novocure Ltd (NASDAQ:NVCR) issued its earnings results on Thursday, July, 25th. The medical equipment provider reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.06. The medical equipment provider had revenue of $86.70 million for the quarter, compared to analyst estimates of $78.98 million. Novocure had a negative return on equity of 31.80% and a negative net margin of 13.84%. The business's quarterly revenue was up 41.0% on a year-over-year basis. During the same period last year, the company posted ($0.17) EPS. View Novocure's Earnings History.
When is Novocure's next earnings date?
What price target have analysts set for NVCR?
7 analysts have issued 12 month price targets for Novocure's stock. Their predictions range from $36.00 to $97.00. On average, they anticipate Novocure's share price to reach $68.1429 in the next year. This suggests that the stock has a possible downside of 13.5%. View Analyst Price Targets for Novocure.
What is the consensus analysts' recommendation for Novocure?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novocure.
Has Novocure been receiving favorable news coverage?
Media coverage about NVCR stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novocure earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Novocure.
Are investors shorting Novocure?
Novocure saw a decrease in short interest in August. As of August 31st, there was short interest totalling 4,983,200 shares, a decrease of 5.7% from the July 31st total of 5,283,500 shares. Based on an average trading volume of 824,500 shares, the days-to-cover ratio is presently 6.0 days. Approximately 6.4% of the shares of the stock are sold short. View Novocure's Current Options Chain.
Who are some of Novocure's key competitors?
Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA) and ICU Medical (ICUI).
What other stocks do shareholders of Novocure own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and Rewalk Robotics (RWLK).
Who are Novocure's key executives?
Novocure's management team includes the folowing people:
- Asaf Danziger, Chief Executive Officer & Director
- Mike Ambrogi, Chief Operating Officer
- Wilco Groenhuysen, CFO & Chief Accounting Officer
- Eilon D. Kirson, Chief Science Officer, Head-Research & Development
- Uri Weinberg, Vice President-Clinical Development
Who are Novocure's major shareholders?
Novocure's stock is owned by a number of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (8.99%), Vanguard Group Inc. (6.28%), BlackRock Inc. (5.66%), BlackRock Inc. (5.66%), Price T Rowe Associates Inc. MD (2.40%) and Renaissance Technologies LLC (2.09%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.
Which institutional investors are selling Novocure stock?
NVCR stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Waddell & Reed Financial Inc., Allianz Asset Management GmbH, StepStone Group LP, TimesSquare Capital Management LLC, D. E. Shaw & Co. Inc., Rhenman & Partners Asset Management AB and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.
Which institutional investors are buying Novocure stock?
NVCR stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., BlackRock Inc., BlackRock Inc., Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, Invesco Ltd., Renaissance Technologies LLC and Eagle Asset Management Inc.. View Insider Buying and Selling for Novocure.
How do I buy shares of Novocure?
Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Novocure's stock price today?
One share of NVCR stock can currently be purchased for approximately $78.82.
How big of a company is Novocure?
Novocure has a market capitalization of $7.74 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.
What is Novocure's official website?
How can I contact Novocure?
Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]
MarketBeat Community Rating for Novocure (NASDAQ NVCR)
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
